At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

The firm will pick two lead agents targeting PSMA and CLDN18.2 later this year and a third STEAP1-targeting drug next year.

If there are no dose-limiting toxicities, the company will test the CAR T-cell therapy at higher doses in more patients with FLT3-expressing refractory AML.

SNUG01 showed favorable safety and signs of early clinical efficacy in a recently completed investigator-initiated trial in China, the firm said.

The company will instead focus resources on its last remaining clinical asset, PRT7732, a chemically distinct SMARCA2 degrader.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.

The Rare Therapies Launch Pad pilot aims to create a streamlined path to develop individualized treatments and get them approved.

Fifteen percent of patients who received Skysona within clinical trials have since been diagnosed with hematologic malignancies.

Patients on a combination of toripalimab and RemeGen's anti-HER2 antibody disitamab vedotin fared better than those on a chemotherapy regimen.